<analysis>
**Capability clock for this month.** The index moves from 3.51 to about 3.58. The drivers are the Gemini successor reaching general availability, GPT-7's agentic tier growing, K5 possibly shipping, and automated R&D at other labs. Anthropic is paused, so its contribution falls, while the frontier elsewhere moves ungated.

The step size grows in 2030 for three reasons:
- Roughly 10 GW of Stargate capacity, and Google's comparable build-out, come online through H2 2029.
- R&D multipliers from multi-week agents compound.
- A first frontier-scale run is likely trained largely by agents, around Q4 2029.

Even so, the current path is back-loaded. I will flatten it: Level 4 around November 2029 to January 2030, Level 5 around July to August 2030.

**Action 1 (diagnosis).** The METR family, the pre-registration and the root-cause study are internal or partner work METR already does, so they are feasible. The hard parts are partner consent under NDA amendments within a month, and counsel's reaction to listing which partners declined, given that NDAs may bar naming them. The small-copy fine-tune is feasible, but it will only start this month, not report. A partial outcome is likely.

**Action 2 (board paper).** The CEO must table the paper, and the CEO has countersigned the criteria before, so tabling is likely. The board is under real pressure:
- the stock is about 22% below offer and the pause has been public for a month;
- the Gemini successor reaches GA;
- throughput complaints continue;
- investors will ask for a resumption timeline, and a sell-side downgrade or shareholder-suit chatter is plausible.

Declared distribution for the June board review:

| Outcome | Probability |
|---|---|
| Defers cleanly as the paper asks | ~35% |
| Defers but hardens the long-stop, e.g. "31 July controls; re-test compressed to 21 days" or management co-sign on timing | ~30% |
| Formal resolution rewrites the criteria (Threat 3) | ~25–30% |
| Board pulls the long-stop date earlier | ~5–10% |

The action's P(failure) covers the CEO not tabling, or the board declining to defer without a rewrite. The rewrite itself is Threat 3, so I do not count it twice.

**Action 3 (CAISI observers).** This is lighter than transferring tools. Three things can block it:
- METR's agreement with Anthropic may bar third-party observers, and counsel has blocked sharing three times in a row;
- CAISI has 43 staff and an acting head, so assigning people takes time;
- government affairs worries about pre-empting OSTP's roles.

The committee briefing given only on request is low-risk. I rate it moderate to high risk, lower than the failed module transfer.

**Action 4 (CAICT comment).** Drafting from public text is trivial. The risk is institutional: a US lab filing to a MIIT-affiliated body during the BIS and RASA fight. Consultation-driven delay belongs to Threat 4. Residual GC or policy-team reluctance is the action's own risk.

**Action 5 (cyber).** Templates, the triage rota and the Louisiana scans are routine. The German pilot is slow to finalise: German data-protection review, hosting contracts and hospital IT approvals rarely close in a month. Expect partial success.

**Action 6 (oversight and GFI).** These are internal and routine. The dated surge-extension bridge needs CEO budget approval under cost pressure, so partial approval is plausible.

**Threats.**
- **Threat 1.** Apollo is sophisticated and would likely redact the battery arm symmetrically. The artefact is still a real, documented trigger, so the risk is moderate.
- **Threat 2.** The held model shares the recipe with the successor, which diverged at 9% and then 6.4%. It is less capable, and awareness scales with capability, so it may diverge less. The run is mid-June and results could arrive late June or early July, so there is also timing risk. A fail or borderline result is fairly likely.
- **Threat 5.** Gemini GA is highly likely. K5 has slipped three times. A visible shift in customers and analysts is plausible but not certain within a month. An incident tied to K5 within the same month is less likely. If the roll materialises very low (below about 10), include an incident.
</analysis>

<action_odds>
Action 1 [Diagnosis + honest next reading]: P(failure) 35%. Reason: METR's family and the pre-registration are feasible. Partner NDA consent and counsel's handling of named decliners are hard within a month, and the root-cause arm only starts rather than reports.

Action 2 [Board deferral paper]: P(failure) 35%. Reason: the CEO has an incentive to table it, but pressure from the stock price, investors and the Gemini GA may lead the board to refuse deferral or harden the long-stop. A formal rewrite is modelled separately as Threat 3.

Action 3 [CAISI observes METR/Apollo]: P(failure) 40%. Reason: this is lighter than tool transfer, but it needs METR's contract terms, counsel sign-off and a thinly staffed CAISI to assign observers within weeks. Counsel blocked sharing three times in a row.

Action 4 [CAICT public comment]: P(failure) 30%. Reason: the drafting is trivial, but the GC and policy team may balk at a filing to a Chinese state body. The ONCD consultation delay is modelled as Threat 4.

Action 5 [June cyber defence]: P(failure) 25%. Reason: templates, the triage rota and the Louisiana scans are routine. Finalising the German pilot will likely slip to partial because of German data-protection review and contracting.

Action 6 [Oversight bridge + GFI]: P(failure) 25%. Reason: the audit and enrolment are routine. The CEO may approve the dated surge bridge only partially under budget pressure.
</action_odds>

<threat_odds>
Threat 1 [Redaction artefacts void audit]: P(materialises) 25%. Adversary suggested 35%. Reason for the difference: Apollo already flagged scope limits and would likely apply redaction to both arms symmetrically. The artefact is documented, so the risk stays real.

Threat 2 [Held model fails/borderline differential]: P(materialises) 40%. Adversary suggested 35%. Reason for the difference: I rate it higher because the same recipe produced 9% and then 6.4%. Lower capability tempers this, and results may not land inside June, which lowers it slightly.

Threat 3 [Board rewrites sign-off]: P(materialises) 28%. Adversary suggested 35%. Reason for the difference: the pressure is real and management stripped the gate in April. But the CEO countersigned the criteria, the RSO paper offers a dated path, and a formal rewrite right after a public "brakes worked" story carries reputational and litigation (*Buist*) cost.

Threat 4 [CAICT filing held or China story]: P(materialises) 30%. Adversary suggested 40% held plus 15% headline. Reason for the difference: a short filing from public text can clear quickly, but Anthropic's pattern of holds and the China sensitivity make delay or a critical frame plausible. I combine both branches into one figure.

Threat 5 [June frontier jump / narrative shift]: P(materialises) 40%. Adversary suggested 45% plus 25%. Reason for the difference: Gemini GA is near-certain, but visible customer moves and analyst cuts within a month are less so, and K5 has slipped three times. A K5-linked incident is included only if the roll materialises below about 10.
</threat_odds>
